{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:47:28Z","timestamp":1773161248723,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jns.2026.125795","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:10:56Z","timestamp":1770311456000},"page":"125795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CSF and plasma GFAP and VEGF in adult type 3 spinal muscular atrophy patients treated with nusinersen"],"prefix":"10.1016","volume":"482","author":[{"given":"Ana Catarina","family":"Pronto-Laborinho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Gomes","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamede","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Oliveira Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jns.2026.125795_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol."},{"issue":"6266","key":"10.1016\/j.jns.2026.125795_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"issue":"10063","key":"10.1016\/j.jns.2026.125795_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jns.2026.125795_bb0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jns.2026.125795_bb0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.jns.2026.125795_bb0030","doi-asserted-by":"crossref","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"issue":"5\u20136","key":"10.1016\/j.jns.2026.125795_bb0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2022.189","article-title":"An overview of the therapeutic strategies for the treatment of spinal muscular atrophy","volume":"34","author":"Li","year":"2023","journal-title":"Hum. Gene Ther."},{"issue":"17","key":"10.1016\/j.jns.2026.125795_bb0040","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1111\/jcmm.16802","article-title":"Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen","volume":"25","author":"Johannsen","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.125795_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-019-09547-y","article-title":"Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen","volume":"267","author":"Wurster","year":"2020","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.125795_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"9","key":"10.1016\/j.jns.2026.125795_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2018-320033","article-title":"Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen","volume":"90","author":"Winter","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2026.125795_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2026.125795_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1394001","article-title":"Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia","volume":"15","author":"Brku\u0161anin","year":"2024","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.125795_bb0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14953","article-title":"Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy","volume":"153","author":"Kessler","year":"2020","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.jns.2026.125795_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-57185-w","article-title":"Troponin T is elevated in a relevant proportion of patients with 5q-associated spinal muscular atrophy","volume":"14","author":"Lapp","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jns.2026.125795_bb0080","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14718","article-title":"Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type <scp>II<\/scp> and type <scp>III<\/scp>","volume":"30","author":"Lu","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"5","key":"10.1016\/j.jns.2026.125795_bb0085","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213371","article-title":"Long-term dynamics of CSF and serum Neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with Nusinersen","volume":"104","author":"Cordts","year":"2025","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2026.125795_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073810","article-title":"Neurodegeneration biomarkers in adult spinal muscular atrophy (SMA) patients treated with Nusinersen","volume":"25","author":"Andr\u00e9s-Benito","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2026.125795_bb0095","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00415-025-12984-7","article-title":"Long-term CSF responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen","volume":"272","author":"Cebulla","year":"2025","journal-title":"J. Neurol."},{"issue":"36","key":"10.1016\/j.jns.2026.125795_bb0100","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.1578-17.2017","article-title":"Effects of astroglia on motor neurons in spinal muscular atrophy","volume":"37","author":"Verheijen","year":"2017","journal-title":"J. Neurosci."},{"issue":"17","key":"10.1016\/j.jns.2026.125795_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddx230","article-title":"Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy","volume":"26","author":"Sison","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"21","key":"10.1016\/j.jns.2026.125795_bb0110","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.3472-16.2017","article-title":"Decreased motor neuron support by SMA astrocytes due to diminished MCP1 secretion","volume":"37","author":"Martin","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2026.125795_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2015.10.008","article-title":"Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis","volume":"26","author":"Benninger","year":"2016","journal-title":"J. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2026.125795_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/mus.21323","article-title":"Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathies","volume":"40","author":"Notturno","year":"2009","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.jns.2026.125795_bb0125","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/hmg\/ddab365","article-title":"Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples","volume":"31","author":"Welby","year":"2022","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.jns.2026.125795_bb0130","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/glia.22522","article-title":"Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production","volume":"61","author":"McGivern","year":"2013","journal-title":"Glia"},{"issue":"14","key":"10.1016\/j.jns.2026.125795_bb0135","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1093\/hmg\/ddv148","article-title":"Astrocytes influence the severity of spinal muscular atrophy","volume":"24","author":"Rindt","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.jns.2026.125795_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/neurolint17030041","article-title":"Glial cells in spinal muscular atrophy: speculations on non-cell-autonomous mechanisms and therapeutic implications","volume":"17","author":"Belan\u010di\u0107","year":"2025","journal-title":"Neurol. Int."},{"issue":"2","key":"10.1016\/j.jns.2026.125795_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/88842","article-title":"Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration","volume":"28","author":"Oosthuyse","year":"2001","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.jns.2026.125795_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/S0896-6273(04)00082-0","article-title":"Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration","volume":"41","author":"Sopher","year":"2004","journal-title":"Neuron"},{"issue":"1\u20132","key":"10.1016\/j.jns.2026.125795_bb0155","article-title":"Phosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALS","volume":"18","author":"Gon\u00e7alves","year":"2017","journal-title":"Amyotroph. Lateral Scler. Frontotempor. Degener."},{"issue":"OCT","key":"10.1016\/j.jns.2026.125795_bb0160","article-title":"The central biobank and virtual biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases","volume":"6","author":"Reijs","year":"2015","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2026.125795_bb0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/ng1211","article-title":"VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death","volume":"34","author":"Lambrechts","year":"2003","journal-title":"Nat. Genet."},{"issue":"21","key":"10.1016\/j.jns.2026.125795_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153430","article-title":"Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect","volume":"132","author":"Zhou","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jns.2026.125795_bb0175","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/jnc.13399","article-title":"Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration","volume":"136","author":"Ishiki","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2026.125795_bb0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neures.2023.09.002","article-title":"Protein biomarkers for the diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"197","author":"Donini","year":"2023","journal-title":"Neurosci. Res."},{"issue":"4","key":"10.1016\/j.jns.2026.125795_bb0185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of Nusinersen in longstanding adult 5q-SMA type 3 \u2013 a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"issue":"6","key":"10.1016\/j.jns.2026.125795_bb0190","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1007\/s10072-024-07515-7","article-title":"Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function","volume":"45","author":"Serr\u00e3o","year":"2024","journal-title":"Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:30:57Z","timestamp":1771680657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S0022510X26000778"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125795","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CSF and plasma GFAP and VEGF in adult type 3 spinal muscular atrophy patients treated with nusinersen","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125795"}}